Your session is about to expire
← Back to Search
Neoantigen Vaccine + Immune Checkpoint Blockade for Colorectal Cancer
Study Summary
This trial is testing a new cancer treatment regime that includes two new drugs alongside existing ones, to see if it is more effective than the existing treatment. The primary objective is to see if the new regime extends progression-free survival.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Who is running the clinical trial?
Media Library
- My tumor has a low mutation rate.My cancer has a DNA Polymerase Epsilon mutation.My cancer has a BRAFV600E mutation.I have had pneumonitis treated with steroids, except for lung inflammation from radiation that's resolved.I have a bleeding disorder or often bruise or bleed a lot after shots or blood tests.I have had a transplant of tissue or an organ from another person.I am fully active or can carry out light work.I haven't had any other cancer in the past 2 years, except for one that was treated with the intent to cure.I have metastatic colorectal cancer and am starting or have just started first-line treatment.My cancer has spread, cannot be surgically removed, and can be measured.My organs are functioning well.I do not have active tuberculosis, significant recent infections, hepatitis B or C, or HIV.I have brain metastases that are worsening or causing symptoms.I haven't had a heart attack or serious heart issues in the last 3 months.My cancer is identified as having mismatch repair deficiency or high microsatellite instability.
- Group 1: Vaccine Arm
- Group 2: Control Arm
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any other ongoing or previous clinical trials involving GRT-C901?
"There are 1254 ongoing clinical trials investigating GRT-C901. Of these, 293 have reached Phase 3 status. Many of the trials related to GRT-C901 are located in Guangzhou, Guangdong; however, there are 63018 total research sites running similar experiments."
To what purpose is GRT-C901 most often employed?
"GRT-C901 has shown efficacy in treating cancers that have progressed after treatment with fluoropyrimidine, oxaliplatin and irinotecan. Additionally, it can also ameliorate metastatic ureter urothelial carcinoma, malignant neoplasms, and persistent cervical cancer."
Are we still enrolling patients for this experiment?
"The trial is recruiting patients, with the most recent update to the clinicaltrials.gov listing being on 10/27/2022. It was initially posted on 2/12/2022."
From how many different sites is this experiment being coordinated?
"Presently, this study is recruiting patients from 51 medical facilities. These include Prisma Health in Greenville, South carolina; Sansum Clinic - USOR in Santa Barbara, California; Allegheny General Hospital in Pittsburgh, Pennsylvania; and 48 other locations."
How many people are being enrolled in this trial?
"In order to carry out this clinical trial, 665 individuals that meet the pre-determined inclusion criteria must agree to participate. These potential participants are sourced from different locations, two of which being Prisma Health in Greenville, South carolina and Sansum Clinic - USOR in Santa Barbara, California."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger